{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:44:28Z","timestamp":1786729468421,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi and AstraZeneca Colombia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40121-026-01382-9","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:22:05Z","timestamp":1783520525000},"page":"2455-2476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia"],"prefix":"10.1007","volume":"15","author":[{"given":"Maria","family":"Carrasquilla-Sotomayor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-214X","authenticated-orcid":false,"given":"Nelson J.","family":"Alvis-Zakzuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfrido","family":"Coronell-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Moyano-Tamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Alvarado-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"De la Hoz-Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Alvis-Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.anpede.2023.09.006","volume":"99","author":"L Francisco","year":"2023","unstructured":"Francisco L, Cruz-Ca\u00f1ete M, P\u00e9rez C, et al. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). An Pediatr (Engl Ed). 2023;99:257\u201363. https:\/\/doi.org\/10.1016\/j.anpede.2023.09.006.","journal-title":"An Pediatr (Engl Ed)"},{"key":"1382_CR2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5\u00a0years in 2019: a systematic analysis. Lancet. 2022;399:2047\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0.","journal-title":"Lancet"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ppul.22781","volume":"49","author":"DA Rodr\u00edguez","year":"2014","unstructured":"Rodr\u00edguez DA, Rodriguez-Martinez CE, C\u00e1rdenas AC, et al. Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatr Pulmonol. 2014;49:269\u201376. https:\/\/doi.org\/10.1002\/ppul.22781.","journal-title":"Pediatr Pulmonol"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jped.2013.04.002","volume":"89","author":"JG Pi\u00f1eros","year":"2013","unstructured":"Pi\u00f1eros JG, Baquero H, Bastidas J, et al. Respiratory syncytial virus infection as a cause of hospitalization in population under 1\u00a0year in Colombia. J Pediatr (Rio J). 2013;89:544\u20138. https:\/\/doi.org\/10.1016\/j.jped.2013.04.002.","journal-title":"J Pediatr (Rio J)"},{"key":"1382_CR5","unstructured":"Instituto Nacional de Salud. Boletin Epidemiologico semana 39 2023. 2023. https:\/\/www.ins.gov.co\/buscador-eventos\/BoletinEpidemiologico\/2023_Bolet%C3%ADn_epidemiologico_semana_39.pdf."},{"key":"1382_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/v13040696","author":"M Suryadevara","year":"2021","unstructured":"Suryadevara M, Domachowske JB. Epidemiology and seasonality of childhood respiratory syncytial virus infections in the Tropics. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13040696.","journal-title":"Viruses"},{"key":"1382_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2079322","volume":"18","author":"E Baraldi","year":"2022","unstructured":"Baraldi E, Checcucci Lisi G, Costantino C, et al. RSV disease in infants and young children: can we see a brighter future? Hum Vaccin Immunother. 2022;18:2079322. https:\/\/doi.org\/10.1080\/21645515.2022.2079322.","journal-title":"Hum Vaccin Immunother"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","volume":"3","author":"C Wegzyn","year":"2014","unstructured":"Wegzyn C, Toh LK, Notario G, et al. Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther. 2014;3:133\u201358. https:\/\/doi.org\/10.1007\/s40121-014-0046-6.","journal-title":"Infect Dis Ther"},{"key":"1382_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121317","volume":"12","author":"M Ricc\u00f2","year":"2024","unstructured":"Ricc\u00f2 M, Abu-Raya B, Icardi G, et al. Respiratory syncytial virus: a WAidid consensus document on new preventive options. Vaccines. 2024;12:1317. https:\/\/doi.org\/10.3390\/vaccines12121317.","journal-title":"Vaccines"},{"key":"1382_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9:eaaj1928. https:\/\/doi.org\/10.1126\/scitranslmed.aaj1928.","journal-title":"Sci Transl Med"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275.","journal-title":"N Engl J Med"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","volume":"145","author":"EAF Sim\u00f5es","year":"2025","unstructured":"Sim\u00f5es EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D. Efficacy, safety, and immunogenicity of the MATISSE (Maternal immunization study for safety and efficacy) maternal respiratory syncytial virus prefusion F\u00a0protein vaccine trial. Obstet Gynecol. 2025;145:157\u201367. https:\/\/doi.org\/10.1097\/AOG.0000000000005816.","journal-title":"Obstet Gynecol"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/ppul.25866","volume":"57","author":"CE Rodriguez-Martinez","year":"2022","unstructured":"Rodriguez-Martinez CE, Barbosa-Ramirez J, Acu\u00f1a-Cordero R. Predictors of poor outcomes of respiratory syncytial virus acute lower respiratory infections in children under 5\u00a0years of age in a middle-income tropical country based on the National Public Health Surveillance System. Pediatr Pulmonol. 2022;57:1188\u201395. https:\/\/doi.org\/10.1002\/ppul.25866.","journal-title":"Pediatr Pulmonol"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131. Med Decis Making. 2012;32:667\u201377. https:\/\/doi.org\/10.1177\/0272989X12454577.","journal-title":"Med Decis Making"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"},{"key":"1382_CR16","unstructured":"DANE-Nacimientos 2023. https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/salud\/nacimientos-y-defunciones\/nacimientos\/nacimientos-2023. Accessed 21 Apr 2025."},{"key":"1382_CR17","unstructured":"SISPRO-Sistema Integrado de Informaci\u00f3n de la Protecci\u00f3n Social. https:\/\/www.sispro.gov.co\/Pages\/Home.aspx. Accessed 16 June 2023."},{"key":"1382_CR18","unstructured":"DANE. Situaci\u00f3n de las mujeres rurales desde las estad\u00edsticas oficiales; 2022. https:\/\/www.dane.gov.co\/files\/investigaciones\/notas-estadisticas\/oct-2022-nota-estadistica-mujer-rural-presentacion.pdf."},{"key":"1382_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006602.pub4","author":"T Andabaka","year":"2013","unstructured":"Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD006602.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1382_CR20","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","volume":"226","author":"X Li","year":"2022","unstructured":"Li X, Bilcke J, V\u00e1zquez Fern\u00e1ndez L, et al. Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J Infect Dis. 2022;226:S95-101. https:\/\/doi.org\/10.1093\/infdis\/jiac064.","journal-title":"J Infect Dis"},{"key":"1382_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7:180\u20139. https:\/\/doi.org\/10.1016\/S2352-4642(22)00321-2.","journal-title":"Lancet Child Adolesc Health"},{"key":"1382_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1441786","author":"JF Barbas Del Buey","year":"2024","unstructured":"Barbas Del Buey JF, \u00cd\u00f1igo Mart\u00ednez J, Guti\u00e9rrez Rodr\u00edguez M\u00c1, et al. The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study. Front Public Health. 2024. https:\/\/doi.org\/10.3389\/fpubh.2024.1441786.","journal-title":"Front Public Health"},{"key":"1382_CR23","doi-asserted-by":"publisher","unstructured":"Munro APS, Drysdale SB, Cathie K, et al. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase\u00a03b trial. Lancet Child Adolesc Health. 2025;9:404\u201312. https:\/\/doi.org\/10.1016\/S2352-4642(25)00102-6.","DOI":"10.1016\/S2352-4642(25)00102-6"},{"key":"1382_CR24","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389:2425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2309189.","journal-title":"N Engl J Med"},{"key":"1382_CR25","unstructured":"Drysdale S, et al. Efficacy of nirsevimab against RSV lower respiratory tract infection hospitalization in infants: preliminary data from the HARMONIE phase\u00a03b trial. In: Presented at 41st Annual Meeting of the European Society for Paediatric Infectious Diseases in Lisbon, 2023; 2023."},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1913556.","journal-title":"N Engl J Med"},{"key":"1382_CR27","unstructured":"US Food and Drug Administration. Beyfortus (nirsevimab-alip) prescribing information. Silver Spring (MD): FDA; 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761328s005lbl.pdf. Accessed 21 Apr 2025."},{"key":"1382_CR28","doi-asserted-by":"publisher","unstructured":"Jasset OJ, Lopez Zapana PA, Bahadir Z, et al. Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth. Am J Obstet Gynecol. 2024. https:\/\/doi.org\/10.1016\/j.ajog.2024.10.053.","DOI":"10.1016\/j.ajog.2024.10.053"},{"key":"1382_CR29","unstructured":"Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. https:\/\/stacks.cdc.gov\/view\/cdc\/85252. Accessed 14 Feb 2025."},{"key":"1382_CR30","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. Programa Ampliado de Inmunizaciones (PAI); 2025. https:\/\/www.minsalud.gov.co\/salud\/Paginas\/ProgramaAmpliadodeInmunizaciones(PAI).aspx. Accessed 15 Oct 2025."},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","volume":"41","author":"Z Mao","year":"2023","unstructured":"Mao Z, Li X, Dacosta-Urbieta A, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine. 2023;41:2707\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.024.","journal-title":"Vaccine"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.vhri.2019.07.010","volume":"20","author":"F Salcedo-Mej\u00eda","year":"2019","unstructured":"Salcedo-Mej\u00eda F, Alvis-Zakzuk NJ, Carrasquilla-Sotomayor M, et al. Economic cost of severe acute respiratory infection associated to influenza in Colombian children: a single setting analysis. Value Health Reg Issues. 2019;20:159\u201363. https:\/\/doi.org\/10.1016\/j.vhri.2019.07.010.","journal-title":"Value Health Reg Issues"},{"key":"1382_CR33","unstructured":"Ministerio de Trabajo. Salario m\u00ednimo legal mensual vigente en Colombia a\u00f1o 2023; 2023. https:\/\/www.mintrabajo.gov.co\/prensa\/comunicados\/2022\/diciembre."},{"key":"1382_CR34","unstructured":"Colombia - Estad\u00edsticas Vitales-EEVV 2017\u20132018. https:\/\/microdatos.dane.gov.co\/index.php\/catalog\/652\/data-dictionary. Accessed 21 Apr 2025."},{"key":"1382_CR35","unstructured":"Colombia-Estad\u00edsticas Vitales-EEVV. 2019. https:\/\/microdatos.dane.gov.co\/index.php\/catalog\/696\/data-dictionary. Accessed 21 Apr 2025."},{"key":"1382_CR36","unstructured":"Colombia-Estad\u00edsticas Vitales-EEVV. 2022. https:\/\/microdatos.dane.gov.co\/index.php\/catalog\/807. Accessed 21 Apr 2025."},{"key":"1382_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0123-0","volume":"5","author":"L Bont","year":"2016","unstructured":"Bont L, Checchia P, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western Countries. Infect Dis Ther. 2016;5:3. https:\/\/doi.org\/10.1007\/s40121-016-0123-0.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1382_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-14-261","volume":"14","author":"LR Krilov","year":"2014","unstructured":"Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr. 2014;14(1):261. https:\/\/doi.org\/10.1186\/1471-2431-14-261.","journal-title":"BMC Pediatr"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jval.2022.11.014","volume":"26","author":"X Li","year":"2023","unstructured":"Li X, Hodgson D, Flaig J, et al. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023;26:508\u201318. https:\/\/doi.org\/10.1016\/j.jval.2022.11.014.","journal-title":"Value Health"},{"key":"1382_CR40","doi-asserted-by":"crossref","unstructured":"Han H, Jang S, Ryu D, Bae E, Soudani S, Suh H. EE416 cost-effectiveness analysis of nirsevimab prophylaxis for prevention of respiratory syncytial virus disease among infants in South Korea. In: Value in Health. Elsevier; 2024;27:S137.","DOI":"10.1016\/j.jval.2024.10.697"},{"key":"1382_CR41","unstructured":"Gui\u00f1az\u00fa G, Dvorkin J, Mahmud S, et al. Evaluation of the impact and cost-effectiveness of respiratory syncytial virus prevention strategies for infants in Argentina. Available at SSRN 4754920."},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388:1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480.","journal-title":"N Engl J Med"},{"key":"1382_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","volume":"7","author":"EAF Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7:87\u2013120. https:\/\/doi.org\/10.1007\/s40121-018-0188-z.","journal-title":"Infect Dis Ther"},{"key":"1382_CR44","unstructured":"Malo DC, Pulido PA. Informe de evento infeccion respiratoria aguda, Colombia, 2017; 2018."},{"key":"1382_CR45","unstructured":"S\u00e1nchez DCM, Molano SLB. Informe de evento infeccion respiratoria aguda, Colombia, 2019; 2019."},{"key":"1382_CR46","unstructured":"Molano SLB, Acero DMW. Informe de evento Infecci\u00f3n Respiratoria Aguda; 2022."},{"key":"1382_CR47","doi-asserted-by":"publisher","DOI":"10.33610\/infoeventos.10","volume-title":"Informe de Evento 2023 Infecci\u00f3n Respiratoria Aguda","author":"Instituto Nacional de Salud","year":"2023","unstructured":"Instituto Nacional de Salud. Informe de Evento 2023 Infecci\u00f3n Respiratoria Aguda. Instituto Nacional de Salud - Direcci\u00f3n de Vigilancia y An\u00e1lisis del Riesgo en Salud P\u00fablica; 2023. https:\/\/doi.org\/10.33610\/infoeventos.10."},{"key":"1382_CR48","doi-asserted-by":"crossref","unstructured":"Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18.","DOI":"10.1186\/s12916-020-01537-6"},{"key":"1382_CR49","unstructured":"Pages-SISMED-Sistema de Informaci\u00f3n de Precios de Medicamentos. https:\/\/www.sispro.gov.co\/central-prestadores-de-servicios\/Pages\/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx. Accessed 15 Apr 2024."},{"key":"1382_CR50","unstructured":"Datos Abiertos (datos.gov.co). https:\/\/www.minsalud.gov.co\/Paginas\/datos-abiertos.aspx. Accessed 21 Apr 2025."},{"issue":"1","key":"1382_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.aller.2019.04.004","volume":"48","author":"CE Rodr\u00edguez-Mart\u00ednez","year":"2020","unstructured":"Rodr\u00edguez-Mart\u00ednez CE, Sossa-Brice\u00f1o MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergologia et Immunopathologia. 2020;48(1):56\u201361. https:\/\/doi.org\/10.1016\/j.aller.2019.04.004.","journal-title":"Allergologia et Immunopathologia"},{"key":"1382_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270086","volume":"17","author":"L Castillo-Rodr\u00edguez","year":"2022","unstructured":"Castillo-Rodr\u00edguez L, Malo-S\u00e1nchez D, D\u00edaz-Jim\u00e9nez D, Garc\u00eda-Vel\u00e1squez I, Pulido P, Casta\u00f1eda-Orjuela C. Economic costs of severe seasonal influenza in Colombia, 2017\u20132019: a multi-center analysis. PLoS One. 2022;17:e0270086. https:\/\/doi.org\/10.1371\/journal.pone.0270086.","journal-title":"PLoS One"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01382-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:24:12Z","timestamp":1786728252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01382-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01382-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (Maria Carrasquilla-Sotomayor, Nelson J. Alvis-Zakzuk, Wilfrido Coronell- Rodr\u00edguez, Andres Arias, Lina Moyano-Tamara, Juan Carlos Alvarado-Gonzalez, Fernando De la Hoz-Restrepo, Nelson Alvis-Guzman) declare no conflicts of interest related to the conduct, interpretation, or publication of this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}